You are here

SCIKON INNOVATION, INC.

Company Information
Address
2 DAVIS DR STE 209
RESEARCH TRIANGLE PARK, NC 27709-0003
United States


https://www.scikoninnovation.com

Information

UEI: GB8YLLHKNLB3

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Standardization of a Fluidic In Vitro Exposure System for IVIVE Predictive Toxicity Data

    Amount: $1,592,960.00

    Project Summary The high failure rate of drugs late in clinical development is an indication that nonclinical in vitro models and animal models are not accurately predicting compound performance in hu ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Microfluidic Biotool to Accurately Model Corrosive Chemical Exposures for Human

    Amount: $225,000.00

    Project Summary There is a critical gap between the need to evaluate the effect of chemicals on human physiology and the availability of in vivo and in vitro testing systems that provide the necessary ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  3. D Multi Organ Model Using Microfluidics to Mimic in vivo Compound Exposure

    Amount: $225,000.00

    Project Summary Compounds from the pharmaceutical and other industries undergo safety and efficacy testing but the in vitro and animal models that are used often fail in their translation to human phy ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Low Cost Microphysiological System for Improved Pharmacodynamics

    Amount: $199,623.00

    DESCRIPTION provided by applicant The high failure rate of drugs in late stage development nearly is a symptom of the inadequacy of pre clinical animal models to accurately predict human biol ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  5. Bench-top human metabolism system for improved IVIVE in drug development

    Amount: $169,407.00

    DESCRIPTION provided by applicant Only of investigational drugs that enter clinical trials make it to approval Seventy five percent of these failures are due to either unexpected toxicity or l ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  6. Functionalizing Non-Useable Cryopreserved Human Hepatocytes into Useable Hepatic

    Amount: $297,285.00

    DESCRIPTION (provided by applicant): The first isolated human hepatoctyte 2D culture, in 1981, provided baseline protocols to support freshly isolated and immediately cultured populations. With cryopr ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government